Pancreatic cancer biomarkers

LOC100507412 RNA in extracellular vesicles serves as a biomarker for diagnosing pancreatic cancer, providing a minimally invasive method to differentiate between healthy and pancreatic cancer patients with high accuracy.

JP7589931B2Active Publication Date: 2024-11-26NAT UNIV ASAHIKAWA MEDICAL UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2020010122
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-01-24
Publication Date
2024-11-26
Estimated Expiration
2040-01-24

AI Technical Summary

Technical Problem

Current techniques for diagnosing pancreatic cancer are invasive and lack effective biomarkers for early detection, particularly differentiating between healthy individuals and patients with intraductal papillary mucinous tumors and pancreatic cancer.

Method used

The use of LOC100507412 RNA in extracellular vesicles as a biomarker, analyzed through methods involving extracellular vesicle recovery, RNA preparation, and quantification, utilizing immunoprecipitation or ultracentrifugation, to differentiate between healthy subjects and pancreatic cancer patients.

Benefits of technology

Enables minimally invasive diagnosis of pancreatic cancer with high accuracy, distinguishing between healthy individuals and patients with intraductal papillary mucinous tumors and pancreatic cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007589931000003
    Figure 0007589931000003
  • Figure 0007589931000004
    Figure 0007589931000004
  • Figure 0007589931000001
    Figure 0007589931000001
Patent Text Reader

Abstract

To develop a technique that can diagnose pancreatic cancer with low invasiveness and conveniently.SOLUTION: The present disclosure provides a pancreatic cancer biomarker, comprising LOC100507412 RNA; a pancreatic cancer inspecting method, including analyzing the amount of LOC100507412 RNA in a human-derived extracellular vesicle; and a pancreatic cancer diagnosis reagent, including means for analysis of the amount of LOC100507412 RNA.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a biomarker for pancreatic cancer, a method for testing pancreatic cancer, and a diagnostic reagent for pancreatic cancer. [Background technology]

[0002] In recent years, various techniques have been developed for diagnosing cancer. In particular, there is a demand for development of a technique that can diagnose cancer simply and with minimal invasiveness in order to reduce the burden on subjects.

[0003] Pancreatic cancer is known to be highly malignant. Intraductal papillary mucinous neoplasm (IPMN) is known to be a tumor that may be associated with pancreatic cancer. IPMN is considered a risk factor for pancreatic carcinogenesis, and patients with IPMN are known to develop pancreatic cancer at a rate of about 1 to 2% per year. Differentiation between healthy individuals and pancreatic cancer patients, and between intraductal papillary mucinous neoplasm patients and pancreatic cancer patients, is clinically important, and therefore there is a demand for the development of minimally invasive and simple techniques that enable such diagnoses.

[0004] Patent Document 1 reports the analysis of the amount of multiple long non-coding RNAs (lncRNAs) as a minimally invasive technique that can easily distinguish between healthy subjects and patients with intraductal papillary mucinous neoplasms or pancreatic cancer. lncRNAs are functional RNAs composed of 200 or more ribonucleotide residues, but the functions of most lncRNAs are unknown.

[0005] Incidentally, LOC100507412 RNA expressed from genomic DNA (SEQ ID NO: 1) identified by LOCUS number: NR_038958 is registered in the database as one of the lncRNAs. However, as far as the present inventors know, there have been no reports of any findings other than the sequence information of LOC100507412 RNA. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2017-158545 A Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to develop a technique that can diagnose pancreatic cancer simply and minimally invasively. [Means for solving the problem]

[0008] As a result of extensive investigations, the present inventors discovered that LOC100507412 RNA in human extracellular vesicles is an indicator of pancreatic cancer, and thus completed the present invention.

[0009] That is, the present invention is as follows. [1] LOC100507412 A biomarker for pancreatic cancer consisting of RNA. [2] A biomarker for pancreatic cancer according to [1], which is a biomarker for distinguishing between healthy individuals and pancreatic cancer patients, or a biomarker for distinguishing between patients with intraductal papillary mucinous neoplasm of the pancreas and patients with pancreatic cancer. [3] A method for testing pancreatic cancer, comprising analyzing the amount of LOC100507412 RNA in extracellular vesicles obtained from humans. [4] The method according to [3], comprising the following steps (a) to (c): (a) Recovering extracellular vesicles from human blood samples; (b) preparing an RNA sample from the extracellular vesicles; and (c) Analyzing LOC100507412 RNA abundance in RNA samples. [5] The method according to [4], wherein the recovery of extracellular vesicles is carried out by immunoprecipitation. [6] The method according to [5], wherein the immunoprecipitation is carried out using an affinity substance for CD9 or CD63, or both. [7] The method according to [4], wherein the recovery of extracellular vesicles is carried out by ultracentrifugation. [8] Any of the methods according to [4] to [7], wherein the human blood sample is a blood sample from a pancreatic cancer patient. [9] Any of the methods according to [3] to [8], wherein the method for testing for pancreatic cancer is a method for distinguishing between healthy individuals and pancreatic cancer patients, or a method for distinguishing between patients with intraductal papillary mucinous neoplasms and patients with pancreatic cancer.

[10] LOC100507412 A diagnostic reagent for pancreatic cancer, including a means for analyzing RNA quantity.

[11] The diagnostic reagent according to

[10] , wherein the means for analyzing the amount of LOC100507412 RNA is one or more means selected from the group consisting of reverse transcriptase, one or more primers and a probe.

[12] The diagnostic reagent of

[10] or

[11] , further comprising a means for collecting extracellular vesicles. Effect of the Invention

[0010] According to the present invention, pancreatic cancer can be diagnosed simply and minimally invasively. The present invention is also useful for distinguishing between healthy subjects or patients with intraductal papillary mucinous neoplasms and patients with pancreatic cancer. [Brief description of the drawings]

[0011] [Figure 1] Figure 1 shows the genomic DNA sequence encoding LOC100507412 (LOCUS number: NR_038958), a long non-coding RNA (lncRNA). The PCR primers used in the examples were designed to correspond to the nucleotide region from 583 to 610 (underlined) and the nucleotide region from 700 to 717 (underlined). The PCR amplified fragment was detected with a probe corresponding to the nucleotide region from 613 to 630 (italicized). [Diagram 2] Figure 2 shows an analysis of LOC100507412 RNA levels in extracellular vesicle-derived RNA (EV RNA) prepared from serum from 20 healthy individuals (Control), 20 patients with intraductal papillary mucinous neoplasm (IPMN), and 20 patients with pancreatic cancer (PDAC). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The present invention provides a biomarker for pancreatic cancer consisting of LOC100507412 RNA.

[0013] LOC100507412 RNA is a long non-coding RNA (lncRNA) expressed from genomic DNA (SEQ ID NO: 1) identified by LOCUS number: NR_038958. LOC100507412 RNA used in the present invention may have one or more naturally occurring mutations (e.g., substitutions, insertions, deletions) of nucleotide residues between races and / or individuals. The number of nucleotide residues in such mutations may be, for example, 1 to 100, preferably 1 to 50, more preferably 1 to 20, even more preferably 1 to 10, and particularly preferably 1, 2, 3, 4, or 5.

[0014] Previously, no findings other than sequence information about LOC100507412 RNA have been reported, and the function and use of the RNA have been completely unknown. However, the present inventors have now found that LOC100507412 RNA is useful for diagnosing pancreatic cancer, and the usefulness of the RNA has been revealed for the first time. For example, LOC100507412 RNA is useful for distinguishing between healthy individuals or patients with intraductal papillary mucinous tumors and patients with pancreatic cancer. In addition, by combining the present invention with other techniques that can distinguish between healthy individuals and patients with intraductal papillary mucinous tumors, it is also possible to determine whether a subject is healthy, has intraductal papillary mucinous tumors, or suffers from pancreatic cancer.

[0015] The present invention also provides a method for testing pancreatic cancer, comprising analyzing the amount of LOC100507412 RNA in extracellular vesicles obtained from humans.

[0016] Extracellular vesicles are minute vesicles having a membrane structure secreted from various types of cells. Examples of extracellular vesicles include exosomes, ectosomes, and apoptotic vesicles. Preferably, the extracellular vesicles are exosomes. Extracellular vesicles can also be defined by their size. The size of the extracellular vesicles is, for example, 30 to 1000 nm, preferably 50 to 300 nm, and more preferably 80 to 200 nm. The size of the extracellular vesicles can be measured using NanoSight (Malvern Instruments).

[0017] Extracellular vesicles can also be defined by extracellular vesicle markers. Such extracellular vesicle markers include, for example, internal markers and surface markers of extracellular vesicles. Internal markers of extracellular vesicles include, for example, carcinoembryonic antigen (CEA), CA125, CA15-3, actin family, TSG101, ALIX, charged multivesicular body protein (CHMP) family, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), poly(ADP-ribose) polymerase (PARP) family, AFP, CA19-9, CA125, flotillin-I, flotillin-II, Rab protein, programmed cell death (PDCD)6, phospholipid scramblase (PLSCR) family, cytochrome C oxidase (COX) family, lamin family, proliferating cell nuclear antigen (PCNA), tubulin family, TATA binding protein (TBP), voltage-dependent anion channel protein (VDAC), amyloid beta, and tau protein. Examples of surface markers of extracellular vesicles include tetraspanin membrane proteins (extracellular vesicle membrane-specific four-spanning membrane proteins, e.g., CD9, CD63, CD81), extracellular matrix metalloprotease inducers (e.g., CD147), heat shock protein (HSP) 70, HSP90, major histocompatibility complex (MHC) I, lysosome-associated membrane protein (LAMP) 1, intercellular adhesion molecule (ICAM)-1, integrins, ceramide, cholesterol, phosphatidylserine, Annexins, Caveolin-I, and EpCAM. The extracellular vesicle marker is preferably an extracellular vesicle surface marker, more preferably a tetraspanin membrane protein, and even more preferably CD9 and / or CD63.

[0018] The extracellular vesicles used in the present invention are not particularly limited as long as they are obtained from humans. As such extracellular vesicles, those collected from human samples can be used. As the human sample, any sample containing extracellular vesicles containing LOC100507412 RNA can be used. Preferably, the human sample is a human blood sample. As the human blood sample, human whole blood samples, human plasma samples, and human serum samples can be used, with human serum samples being preferred.

[0019] The method of the present invention may be carried out, for example, by a method including the following (a) to (c): (a) Recovering extracellular vesicles from human blood samples; (b) preparing an RNA sample from the extracellular vesicles; and (c) Analyzing LOC100507412 RNA abundance in RNA samples.

[0020] The recovery in (a) can be performed by any method capable of recovering extracellular vesicles from a human blood sample, such as the guanidine cesium chloride ultracentrifugation method and the AGPC (Acid Guanidinium-Phenol-Chloroform) method.

[0021] In addition, the recovery in (a) may be a method capable of recovering extracellular vesicles from a human blood sample with high efficiency. For example, such a highly efficient recovery method may include treating an extracellular-containing sample with a chelating agent, and then isolating extracellular vesicles from the extracellular-containing sample treated with the chelating agent (International Publication No. WO 2018 / 070479).

[0022] The chelating agent is a compound or a salt thereof having a coordination moiety capable of coordinate bonding with a metal ion. The number of coordination moieties is preferably 2 or more, more preferably 3 or more (e.g., 3 or 6). Examples of the coordination atom as the coordination moiety include an oxygen atom, a phosphorus atom, a nitrogen atom, a sulfur atom, and a chlorine atom. The coordination atom is preferably an oxygen atom or a phosphorus atom, more preferably an oxygen atom. Examples of the coordination group as the coordination moiety include a group having the above-mentioned coordination atom. The coordination group is preferably a carboxylic acid group or a phosphoric acid group, more preferably a carboxylic acid group.

[0023] Examples of the chelating agent include hydroxyethyliminodiacetic acid (HIDA), nitrilotriacetic acid (NTA), hydroxyethylethylenediaminetriacetic acid (HEDTA), ethylenediaminetetraacetic acid (EDTA), ethylenediaminetetra(methylenephosphonic acid) (EDTMP), glycoletherdiaminetetraacetic acid (EGTA), and salts thereof. Examples of the salt include metal salts (e.g., monovalent metal salts such as sodium salts and potassium salts, and divalent metal salts such as calcium salts and magnesium salts), inorganic salts (e.g., halide salts such as fluorides, chlorides, bromides, and iodides, and ammonium salts), organic salts (e.g., ammonium salts substituted with an alkyl group), and acid addition salts (e.g., salts with inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, nitric acid, and phosphoric acid, and salts with organic acids such as acetic acid, oxalic acid, lactic acid, citric acid, trifluoromethanesulfonic acid, and trifluoroacetic acid).

[0024] The chelating agent may also be a chelating agent that is commonly used as a component contained in blood collection tubes for clinical testing.Such chelating agents include, for example, EDTA, EGTA, NTA, HEDTA, EDTMP, HIDA, citric acid and their salts.In the present invention, the use of such chelating agents is also desirable from the viewpoint of clinical application.

[0025] In the present invention, one type of chelating agent may be used alone, or multiple types (eg, two, three, or four) of chelating agents may be used in combination.

[0026] The concentration of the chelating agent when acting on a human blood sample is not particularly limited as long as it is a concentration that can improve the recovery amount of extracellular vesicles from the human blood sample. In the present invention, in light of the fact that a mixed solution containing extracellular vesicles and a chelating agent is generated by mixing a human blood sample with a chelating agent, the concentration of the chelating agent when acting on a human blood sample is the same as the concentration of the chelating agent in such a mixed solution. Therefore, in the present invention, the concentration of the chelating agent when acting on a human blood sample with a chelating agent can also be defined as the concentration of the chelating agent in such a mixed solution. Such a concentration varies depending on factors such as the type and concentration of other components used in combination with the chelating agent, but is, for example, 10 mM to 1000 mM. Preferably, the concentration of the chelating agent may be 20 mM or more, 30 mM or more, 40 mM or more, 50 mM or more, 60 mM or more, 80 mM or more, or 100 mM or more. Such a concentration may also be 800 mM or less, 600 mM or less, 500 mM or less, 450 mM or less, 400 mM or less, 350 mM or less, or 300 mM or less. More specifically, the concentration of the chelating agent may be 20 to 800 mM, 30 to 600 mM, 40 to 500 mM, 50 to 450 mM, 60 to 400 mM, 80 to 350 mM, or 100 to 300 mM.

[0027] The recovery of extracellular vesicles from human blood samples can be carried out, for example, by immunoprecipitation or ultracentrifugation. By analyzing the amount of LOC100507412 RNA after the recovery of human extracellular vesicles, potential contamination with substances that may inhibit the detection of the RNA can be prevented, and the influence of differences between human samples (e.g., contaminants present in human blood samples) can be reduced. Preferably, the recovery can be carried out by immunoprecipitation. When the recovery is carried out by immunoprecipitation, the above-mentioned potential contamination can be more effectively prevented, and the influence of the above-mentioned differences can be more effectively prevented.

[0028] When recovery of extracellular vesicles from a human blood sample is performed by immunoprecipitation, the immunoprecipitation can be performed using an affinity substance for a surface marker of the extracellular vesicles.

[0029] Examples of the affinity substance for the surface marker of extracellular vesicles include the above-mentioned antibodies, aptamers, phosphatidylserine-binding proteins, and ceramide-binding proteins for the surface marker of extracellular vesicles. In the present invention, a single substance or multiple (e.g., two, three, or four) types of substances can be used as the affinity substance for the surface marker of extracellular vesicles.

[0030] Preferably, the affinity substance for the extracellular vesicle surface marker may be an antibody for the extracellular vesicle surface marker from the viewpoints of ensuring specificity for the extracellular vesicle surface marker and ease of preparation. Examples of the antibody include full-length antibodies (e.g., monoclonal antibodies, polyclonal antibodies) and antigen-binding fragments thereof. The antigen-binding fragment may be an antibody fragment that maintains the binding ability to the target extracellular vesicle surface marker, and examples of the antibody fragment include Fab, Fab', F(ab')2, scFv, and the like. In the present invention, a single antibody or multiple types of antibodies (e.g., two, three, four types) can be used.

[0031] The affinity substance for the surface marker of extracellular vesicles (preferably, an antibody) may be immobilized on a solid phase to facilitate the separation of extracellular vesicles. Examples of the solid phase include beads and particles (e.g., sepharose beads, agarose beads, magnetic beads (magnetic particles)), and supports (e.g., plates such as plastic plates, membranes). The immobilization of the substance on the solid phase can be performed by any method. The affinity substance for the surface marker of extracellular vesicles immobilized on the solid phase in this way is mixed with a mixture containing extracellular vesicles to form a complex of the substance that binds to the extracellular vesicle surface marker and the extracellular vesicles, and this complex is separated from the mixture, thereby separating the extracellular vesicles from the mixture. For example, when beads or particles are used as the solid phase, the extracellular vesicles can be separated from the mixture by centrifuging after the formation of the complex and removing the supernatant. When magnetic beads are used as the solid phase, the extracellular vesicles may be separated from the mixture by magnetic collection after the formation of the complex and removing the supernatant. When a support is used as the solid phase, the mixture can be removed after the formation of the complex, thereby separating the extracellular vesicles from the mixture.

[0032] The affinity substance for a surface marker of extracellular vesicles is preferably an affinity substance for a tetraspanin membrane protein, and even more preferably an affinity substance for CD9 and / or CD63.

[0033] The temperature at which the human blood sample is mixed with the affinity substance for the surface marker of the extracellular vesicles is not particularly limited, as long as the affinity substance can bind to the extracellular vesicles and the affinity substance can be used to recover the extracellular vesicles. Such a temperature may be, for example, 4 to 80°C, preferably 35 to 60°C. The time at which the human blood sample is treated with the affinity substance for the surface marker of the extracellular vesicles is not particularly limited, as long as the time is sufficient for the affinity substance to bind to the extracellular vesicles.

[0034] When the recovery of extracellular vesicles from a human blood sample is performed by ultracentrifugation, the ultracentrifugation can be performed using an ultracentrifuge. The gravity applied in ultracentrifugation may be, for example, 10,000×g to 200,000×g, and preferably 70,000×g to 150,000×g. The time of ultracentrifugation is, for example, 0.5 to 24 hours, and preferably 1 to 5 hours. The temperature in ultracentrifugation is, for example, 4 to 30° C. Ultracentrifugation may be performed once or multiple times (e.g., twice or three times).

[0035] The preparation in (b) can be performed by any method capable of preparing an RNA sample from extracellular vesicles. As such a method, any RNA extraction method commonly used in the art can be suitably used.

[0036] The analysis in (c) can be performed by any method capable of analyzing the amount of RNA. Examples of the analysis method for the amount of RNA include gene amplification, hybridization, and sequencing. Examples of the gene amplification method include chanothermal gene amplification (e.g., PCR) and isothermal gene amplification (e.g., LAMP, ICAN). In the gene amplification method, reverse transcriptase can be used in combination. Examples of the hybridization method include microarray and northern blotting. Examples of the sequencing method include the technology described in JP 2017-158545 A.

[0037] Based on the analysis of the amount of LOC100507412 RNA, the possibility of suffering from pancreatic cancer is determined. The result of the analysis of the amount of RNA is used as an index for comparison with a reference value. The subject group suffering from pancreatic cancer has a significantly higher amount of LOC100507412 RNA than the subject group not suffering from pancreatic cancer. Therefore, according to the method of the present invention, when the amount of RNA is equal to or greater than the reference value, it can be determined that the subject is highly likely to suffer from pancreatic cancer. Also, when the amount of RNA is less than the reference value, it can be determined that the subject is low likely to suffer from pancreatic cancer.

[0038] The above-mentioned reference value may be, for example, a cutoff value that is appropriately set so as to distinguish between a group not suffering from pancreatic cancer (healthy individuals and / or intraductal papillary mucinous tumors) and a group suffering from pancreatic cancer. The cutoff value is a value that satisfies both high diagnostic sensitivity (positive diagnosis rate) and high diagnostic specificity (positive diagnosis rate) when a disease is judged based on the cutoff value. Diagnostic sensitivity (or simply sensitivity) is the proportion of subjects who are correctly diagnosed among subjects who have a specific condition. When a "positive" result is obtained for all subjects who have a specific condition, the sensitivity is 100%. Diagnostic specificity (or simply specificity) is the proportion of subjects who are correctly diagnosed among subjects who do not have a specific condition. When a "negative" result is obtained for all subjects who do not have a specific condition, the specificity is 100%. The method of calculating the cutoff value is well known in the art.

[0039] The method of the present invention may also include administering a therapeutic agent for pancreatic cancer (e.g., an anticancer agent for pancreatic cancer) to a patient whose LOC100507412 RNA level is equal to or higher than a reference value. The method of the present invention further including such administration is useful as a treatment for pancreatic cancer.

[0040] The present invention also provides a diagnostic reagent for pancreatic cancer, which comprises a means for analyzing the amount of LOC100507412 RNA.

[0041] Examples of analytical means for the amount of RNA include reverse transcriptase, one or more primers, and a probe. These analytical means may be used in combination. For example, when the amount of RNA is measured, RT-PCR may be performed using reverse transcriptase and two or more primers (and a probe as necessary). A hybridization method may be performed using a probe. Furthermore, a sequencing method may be performed using one primer. The primer and the probe may be labeled with a labeling substance such as a fluorescent substance.

[0042] The diagnostic reagent of the present invention may further comprise a means for recovering extracellular vesicles. Examples of the means for recovering extracellular vesicles include an affinity substance for a surface marker of extracellular vesicles. The affinity substance for the surface marker of extracellular vesicles is as described above. The affinity substance for the surface marker of extracellular vesicles may be immobilized on a solid phase to facilitate separation of extracellular vesicles. Alternatively, when the affinity substance for the surface marker of extracellular vesicles is not immobilized on a solid phase, the diagnostic reagent of the present invention may further comprise a solid phase. The solid phase is as described above. The diagnostic reagent of the present invention is useful, for example, for rapid and simple implementation of the method of the present invention. EXAMPLES

[0043] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.

[0044] Example 1: Analysis of LOC100507412 RNA level, a biomarker for pancreatic cancer RNA exists in blood in multiple forms. For example, RNA includes (a) cell-free RNA (cfRNA), which is free RNA in blood, (b) RNA present in free cells in blood, (c) RNA bound to factors in blood (e.g., stabilizing factors such as proteins), and (d) extracellular vesicle-derived RNA (EV RNA). EV RNA also includes RNA present inside and / or on the surface of EVs, as well as RNA present in specific EVs (e.g., RNA derived from EVs that are positive for tetraspanins such as CD9 and / or CD60). Therefore, in order to evaluate the influence of differences in the detection sensitivity of biomarkers depending on the type of RNA used as the detection target, a method for recovering RNA from blood samples was examined. The methods examined were (1) a method capable of recovering the above-mentioned (a) cfRNA as the main RNA component, (2) a method using ExoQuick (trademark) capable of recovering the above-mentioned (a) to (d), and (3) a method capable of recovering the above-mentioned (d) EV RNA. Serum from five cases of pancreatic cancer patients was used as blood samples.

[0045] (A) RNA recovery from blood samples. (1)cfRNA (main RNA component) cfRNA was extracted from serum using the miRNeasy Mini Kit (QIAGEN). First, 700 μL of QIAzol Lysis Reagent was added to 300 μL of serum, and RNA was extracted according to the protocol. Although this method allows the inclusion of the RNA components (a) to (d) above, it is possible to extract cfRNA as the main RNA component.

[0046] (2)ExoQuick(trademark) According to ExoQuick (trademark) (System Biosciences), it is explained that various RNAs (a) to (d) can be recovered. Therefore, various RNAs were recovered from serum using ExoQuick (trademark). 100 μL of ExoQuick (trademark) was added to 300 μL of serum, and after mixing, the mixture was incubated at 4° C. for 12 hours and centrifuged at 1,500×g for 30 minutes. After centrifugation, the supernatant was discarded and the pellet was recovered. Various RNAs were extracted from this pellet using SeraMir Kit (System Biosciences) according to the protocol.

[0047] (3)EV RNA An equal volume of 300 μL of EDTA / EGTA / PBS solution was added to the serum (final concentration of both EDTA and EGTA: 50 mM) and centrifuged at 15,000 × g for 15 minutes. The supernatant was transferred and ultracentrifuged at 100,000 × g for 1 hour. The supernatant was then discarded and the precipitate was resuspended in EDTA / EGTA / PBS solution to obtain an EV RNA-containing sample. EV RNA was extracted from this EV RNA-containing sample using miRNeasy in the same manner as in (1).

[0048] (B) Analysis of LOC100507412 RNA content in RNA samples. Next, the amount of LOC100507412 RNA was analyzed for each RNA sample extracted in (1) to (3). Each RNA sample was subjected to reverse transcription reaction using iScript (BIO-RAD) according to the protocol to obtain cDNA samples. These cDNA samples were used to analyze the amount of LOC100507412 RNA. The amount of LOC100507412 RNA was analyzed using digital PCR (QuantStudio 3D Digital PCR System (Thermo Fisher Scientific)) (for the positions of the pair of primers and TaqMan probe used in digital PCR, see Figure 1 and the brief description of the figure). The results are shown in Table 1. The unit is copies / μL.

[0049] [Table 1]

[0050] As a result, the amount of LOC100507412 RNA was increased in EV RNA (Table 1). This indicates that LOC100507412 RNA is present in extracellular vesicles. It was also confirmed that extracellular vesicle samples are useful for improving the sensitivity of measuring LOC100507412 RNA.

[0051] Example 2: Evaluation of LOC100507412 RNA as a biomarker for pancreatic cancer We analyzed the amount of LOC100507412 RNA in extracellular vesicle-derived RNA (EV RNA) using sera from 20 healthy individuals (control), 20 patients with intraductal papillary mucinous neoplasm (IPMN), and 20 patients with pancreatic cancer (PDAC). First, an equal amount of EDTA / EGTA / PBS solution was added to 300 μL of serum (final concentration of 50 mM for both EDTA and EGTA), and centrifuged at 15,000×g for 15 minutes. The supernatant after centrifugation was transferred and ultracentrifuged at 100,000×g for 1 hour. The supernatant was then discarded, and the precipitate was resuspended in EDTA / EGTA / PBS solution to obtain an EV sample. EV RNA was extracted from this EV sample using miRNeasy in the same manner as in Example 1(A)(1). Next, analysis of the amount of LOC100507412 RNA in EV RNA was performed in the same manner as in Example 1(B). The results are shown in FIG. 2. As a result, several cases of PDAC had significantly higher LOC100507412 RNA levels in EV RNA compared with controls and IPMN (Figure 2). Therefore, LOC100507412 RNA is expected to be useful as a biomarker for pancreatic cancer.

[0052] Example 3: Improving the accuracy of PDAC diagnosis by improving the detection sensitivity of LOC100507412 RNA We investigated whether the type of extracellular vesicle collection method affects the accuracy of PDAC determination. We compared immunoprecipitation and ultracentrifugation as methods for collecting extracellular vesicles. Blood samples were used from 20 healthy subjects (control), 20 patients with intraductal papillary mucinous neoplasm (IPMN), and 20 patients with pancreatic cancer (PDAC).

[0053] First, EV samples were prepared by immunoprecipitation. An equal volume of carboxycellulose (CMC) / EDTA / EGTA / PBS solution was added to 300 μL of serum (CMC, final concentration 0.5%, EDTA and EGTA final concentrations 50 mM), and an equal volume of Dynabeads M-280 tosylactivated (Life Technologies) immobilized with anti-CD9 antibody (manufactured in-house) or anti-CD63 antibody (manufactured in-house) was added to the serum at 0.26 mg / mL. After rotating overnight at 4°C, the mixture was washed three times with PBS to obtain EV RNA-containing samples (IP-EV).

[0054] Next, preparation of EV samples by ultracentrifugation was performed in the same manner as in Example 2 (UC-EV).

[0055] For each EV sample prepared by immunoprecipitation and ultracentrifugation, EV RNA was extracted using miRNeasy in the same manner as in Example 1(A)(1). Then, the amount of LOC100507412 RNA in EV RNA was analyzed in the same manner as in Example 1(B). The results are shown in Table 2. The unit is copies / μL.

[0056] [Table 2]

[0057] As a result, in both immunoprecipitation (IP-EV) and ultracentrifugation (UC-EV), the amount of LOC100507412 RNA in EV RNA was significantly higher in PDAC than in control and IPMN. However, in particular, the accuracy of PDAC identification improved with the improved sensitivity of LOC100507412 RNA detection in immunoprecipitation (Table 2). The reason why immunoprecipitation has a higher accuracy of PDAC identification than ultracentrifugation is unclear, but considering that immunoprecipitation can reduce contaminants compared to ultracentrifugation, it is possible that the reduction of contaminants by immunoprecipitation may have prevented the inclusion of substances that may inhibit the detection of LOC100507412 RNA. Therefore, detection of LOC100507412 RNA in RNA samples using extracellular vesicles recovered by immunoprecipitation is expected to be useful as a biomarker for pancreatic cancer with excellent accuracy. [Industrial Applicability]

[0058] The present invention is useful, for example, in clinical testing for pancreatic cancer.

Claims

1. Analyzing the amount of extracellular vesicle-derived LOC100507412 RNA in extracellular vesicles obtained from humans; comparing said amount of RNA to a reference value; and When the amount of RNA is equal to or greater than the reference value, the subject is determined to have a high possibility of having pancreatic cancer, and when the amount of RNA is less than the reference value, the subject is determined to have a low possibility of having pancreatic cancer. Including, The reference value is a cutoff value set so as to distinguish between a group not affected by pancreatic cancer and a group affected by pancreatic cancer. Testing methods for pancreatic cancer.

2. The method according to claim 1, wherein the group not suffering from pancreatic cancer is healthy individuals and / or patients with intraductal papillary mucinous neoplasm.

3. The method according to claim 1 or 2, comprising the following steps (a) to (c): (a) recovering extracellular vesicles from a human blood sample; (b) preparing an RNA sample from the extracellular vesicles; and (c) Analyzing the amount of extracellular vesicle-derived LOC100507412 RNA in RNA samples.

4. The method of claim 3, wherein recovery of extracellular vesicles is performed by immunoprecipitation.

5. The method of claim 4, wherein the immunoprecipitation is carried out using an affinity substance for CD9 or CD63, or both.

6. The method of claim 5, wherein the recovery of extracellular vesicles is performed by ultracentrifugation.

7. The method according to any one of claims 3 to 6, wherein the human blood sample is a blood sample from a pancreatic cancer patient.

8. The method according to any one of claims 1 to 7, wherein the method for testing for pancreatic cancer is a method for distinguishing between healthy subjects and pancreatic cancer patients, or a method for distinguishing between pancreatic intraductal papillary mucinous neoplasm patients and pancreatic cancer patients.

Citation Information

Patent Citations

  • Biomarker for use in the diagnosis of intraductal papillary mucinous neoplasm or pancreatic cancer, and method of inspecting intraductal papillary mucinous neoplasm or pancreatic cancer using the biomarker

    JP2017158545A